WASHINGTON, DC—Administering tranexamic acid during noncardiac surgery provides a clear reduction in bleeding, with a low likelihood of harm in terms of vascular complications, the POISE-3 trial shows ...

A dose of tranexamic acid to start and end noncardiac surgery reduced important bleeding events, the POISE-3 trial showed, albeit with a question mark hanging over cardiovascular risk. The ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Tranexamic acid administered intravenously before and after noncardiac surgery lowered the risk for ...

The antifibrinolytic tranexamic acid (TXA) reduced serious bleeding without a significant effect on major vascular outcomes in patients undergoing noncardiac surgery at risk for these complications in ...

Professor, Michigan State University, East Lansing, Mich. In this multicenter international study, the research teams recruited 20,060 women, 16 years or older, with a clinical diagnosis of postpartum ...

Patients undergoing noncardiac surgery who received a single dose of tranexamic acid (TXA), which promotes blood clotting, at the beginning and end of their surgery had significantly less serious ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous injection of tranexamic acid with lidocaine reduced bleeding during Mohs micrographic surgery, with ...

Use of tranexamic acid (TXA) reduced the risk of major bleeding in patients undergoing urologic surgery, results from the randomized POISE-3 trial showed. Among more than 1,100 patients, 6.1% of those ...

Despite being routinely used in clinical settings, prophylactic use of tranexamic acid, an antifibrinolytic agent administered with platelet transfusions, did not reduce bleeding among patients with ...

Giving tranexamic acid to women with placenta praevia (when the placenta covers the cervical opening) undergoing cesarean birth leads to a significant yet modest reduction in severe bleeding after ...

The WOMAN trial was a single randomized, double-blind, placebo-controlled, multicenter international study consisting of 20,060 females 16 years and older with a diagnosis of PPH after vaginal birth ...